<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="103607">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755676</url>
  </required_header>
  <id_info>
    <org_study_id>ORL60EMS0511</org_study_id>
    <nct_id>NCT01755676</nct_id>
  </id_info>
  <brief_title>Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults</brief_title>
  <official_title>A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg as Adjuvant Treatment of Obesity in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of
      Obesity in adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Orlistat 60 mg associated with diet and exercise in relation to placebo associated with diet and exercise in obesity treatment based on weight loss.</measure>
    <time_frame>112 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>112 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Orlistat 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat 60 mg</intervention_name>
    <description>1 tablet 3 times a day</description>
    <arm_group_label>Orlistat 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet 3 times a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent;

          -  Adults Male and Female ≥ 18 years old;

          -  Obesity (BMI ≥ 30kg/m2 or ≥ 27 Kg/m2 with associate risk);

        Exclusion Criteria:

          -  Pregnancy and Lactation or women without effective contraception;

          -  Relevant clinical diseases;

          -  Obesity associated to genetic syndrome;

          -  Decompensated Diabetes;

          -  Psychiatric disorders;

          -  Alimentary disorders;

          -  Use of: anorectics, herbal weight loss and/or constipation and laxatives, in the past
             30 days;

          -  Patients using cyclosporine or amiodarone;

          -  Patients with bowel disease;

          -  Prior bariatric surgery;

          -  Anemia;

          -  Hemoglobinopathies and coagulopathy;

          -  History of cancer in the past five years;

          -  Use of corticosteroids, oral or injectable, in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto B. Amazonas, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Medicina Reprodutiva Dr Carlos Isaia Filho</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Isaia Filho, MD</last_name>
      <phone>55 51 3222-8180</phone>
    </contact>
    <investigator>
      <last_name>Carlos Isaia Filho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loema</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13010001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio R Santos, MD</last_name>
      <email>contato@loemaipc.com.br</email>
    </contact>
    <investigator>
      <last_name>Fabio R Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro A Crippa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIPMED</name>
      <address>
        <city>Jau</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Tokunaga, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marcio Antonio Pereira Clinica de Endocrinologia</name>
      <address>
        <city>São José dos Campos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcio A. Pereira, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
